Human PD-L1 inhibitor II
Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism.
Human PD-L1 inhibitor II is a peptide-based molecule. It binds to human PD-1 and inhibits PD-1/PD-L1 binding. This peptide, PDL-1 inhibitor I has anchor residues, WDY that influence binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment.
Online Inquiry
| CAT# | X21206 |
| M.W/Mr. | 2219.6 |
| Sequence | One Letter Code: FNWDYSLEELREKAKYK
Three Letter Code: H-Phe-Asn-Trp-Asp-Tyr-Ser-Leu-Glu-Glu-Leu-Arg-Glu-Lys-Ala-Lys-Tyr-Lys-OH |
| References | 1. Bardhan K., et.al, Front Immunol 7(550), (2016);
2. Li Q., et.al, Oncotarget 7(40), 64967-64976 (2016);
3. D'Errico G., et.al, Clin Transl Med 6(1), 3-12 (2017) |
Write a review
Ask a question
My Review for Human PD-L1 inhibitor II
Required fields are marked with *
×
Ask a Question for Human PD-L1 inhibitor II
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
